Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924020 | 1.00 | EPHX2 (0.54) | EPHX2FAAHLMNAGRIN1GRIN2B | |
| SCHEMBL23924231 | 0.85 | EPHX2 (0.48) | EPHX2FAAHLMNA | |
| SCHEMBL23924232 | 0.85 | EPHX2 (0.48) | EPHX2FAAHLMNA | |
| SCHEMBL26932965 | 0.84 | EPHX2 (0.40) | EPHX2FAAH | |
| SCHEMBL30636338 | 0.84 | EPHX2 (0.40) | EPHX2FAAH | |
| SCHEMBL26932969 | 0.84 | EPHX2 (0.40) | EPHX2FAAH | |
| SCHEMBL9279055 | 0.84 | EPHX2 (0.49) | EPHX2FAAH | |
| SCHEMBL16468050 | 0.84 | EPHX2 (0.49) | EPHX2FAAHLMNA | |
| SCHEMBL9279056 | 0.84 | EPHX2 (0.49) | EPHX2FAAH | |
| SCHEMBL9282584 | 0.84 | EPHX2 (0.49) | EPHX2FAAHGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | EPHX2 2416/4885FAAH 4492/4885LMNA 4183/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | EPHX2 2416/4885FAAH 4492/4885LMNA 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.